Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Protagonist Therapeutics, Inc. (PTGX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
31.81-2.46 (-7.18%)
At close: 04:00PM EST
31.81 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement
Sign in to post a message.
  • H
    Horkos
    Love this 102% institutional ownership
  • J
    Jeffrey
    So, it seems if below is correct, the over 60% drop is an over reaction. So, hopefully, this information will become clearer next week and we could see the stock recovering from this monumental drop. Hard to imagine that PTGX would make such a claim right after FDA placed the study on hold if they weren't confident about their findings.

    The document below was filed on Friday and clearly states that PTGX has assessed the cancers and they are not the result of the drug. They are either a preexisting condition or natural disease progression.
  • l
    leonard
    I have practiced Hematology for 40 years at an an academic medical center and care for a large stable of patients with polycythemia vera, which is a chronic disease compatible with decades of life despite progression with time. I had no idea about PT300 until I read about it last Friday. Although the trial only involved 8 patients, I can assure you that this type of response could not be due to chance; it is breathtaking. I don't know Dr. Hoffman personally, but he is a luminary in the field. When he uses the word "revolutionary" for the drug, he is not making an understatement. There is a compelling need for this drug to spare patients the inevitable iron deficiency which occurs with long term phlebotomy therapy, which exacerbates their symptoms, particularly mental acuity. The prospects of self administration of the drug subcutaneously once weekly at home will be hugely appealing to PV patients who are used to seeing the doctor and then being directed to the blood bank for their phlebotomy if indicated, which is usually an all day affair. The drug has been used in over 50 patients with 1000 doses administered and appears to be extremely safe. the principal side effect is local irritation at the injection site, far less then the symptoms associated with phlebotomy. The drug will likely reduce the need for patients to advance to hydroxyurea, a chemotherapy agent with its associated side effects, or interferon, an immune modulater with a long list of side effects. I willl be amazed it the drug doesn't garner orphan drug, breakthrough and fast track designations from the FDA. I think the company's idea to drop its other projects and focus solely on PT300 is astute, and they will have the cash to fund through mid 2022, about the time I think they will be ready for a commercial launch, if not bought out before hand.I would compare this stock to GBT and voxeletor for sickle cell anemia; also a breakthrough drug addressing approximately the same size market of about 100k patients in the US. The difference is that PTGX has a market cap of <400mil while GBT has a market cap approaching 5bil. So I have bought a large amount for me, and will add with any dips
  • B
    BurnEmAway
    I see bad things happening soon here. Cannot give a professional explanation yet but basic overall estimation usually is correct. Might go to $50 and tank. But I think this is its top looking at the revenue.
    Bearish
  • J
    Jeffrey
    Hard to believe that a stock drops 62% over 4 cases of cancer due to preexisting conditions or natural progression of disease. Surely, a very small percentage of mice in all the clinical trials. One analyst, JMP raises pt to $55 from $54, other maintains pt of over $90. Seems like FDA is being extremely cautious with clinical hold. Though, for now, it is only a verbal hold. Maybe, it will be short-lived. Management has clearly stated that these cases are "unrelated" to performance of drug.
  • J
    Jack Georges
    Steve Cohen tripled his PGTX stake. Filing just came out after hours.

    He now has 4.3M shares = 9% stake.
    Shows you confidence pgtx was wayyyyyy oversold this week. See you $18+ by end of week and probably mid $20s by October
  • R
    Rahim
    Can you guys give me a bit of advice. I bought in at $18 as a gamble when it tanked. Do I sell now or hold for more?
  • J
    J
    The cancer found was unrelated to rusfertide, so the hold should be reversed anytime as far as I can see.

    If people did even the tiniest amount of DD they would know this and we could be back in the 40s instead of most people panic selling and day traders penny flipping.

    Know what you hold, have conviction. Spread the word.

    https://investors.protagonist-inc.com/node/9546/html
    SEC Filing | Protagonist Therapeutics, Inc.
    investors.protagonist-inc.com
  • J
    Jeffrey
    JPM just updated price target it looks from 54.14 to 55.14 and maintains a buy rating for the stock. They seem to think that the clinical hold is going to be short-lived.
  • j
    john
    ⚠️ WARNING OF DILUTION IN NEWS RELEASE FRIDAY - WHO CAUGHT IT? THEY CLEARLY PLAN ON SELLING SHARES
    👎 AND I QUOTE: “ ....its adjusted operating plans now provide sufficient financial resources from its cash, cash equivalents, marketable securities ...”
    Those aren’t Tesla shares they bought cheap; LoL 😂 Its their own🚨

    Oh; and GET THIS: $6m MORE BREADING. “Net Loss: The first quarter 2020 👎net loss was $20.1 million, or a net loss of $0.72 per share, as compared to a net loss of $14.1 million, or a net loss of $0.58 per share, for the same period of 2019
    Bearish
  • 1
    12345
    It's nothing wrong to stock fda just put the hold.
    No negative report at all
  • M
    Markssss
    We raised the target to $55 jpm.
    I think the stock will be restored soon.
    Buy more of this.
  • C
    Chan
    How come it is so much lower than its revised target price by all the brokers?
  • E
    Evan
    Hey just started trading with 1000$. Why did you guys invest in this stock. Did you read something somewhere which let you know there was going to be a big jump. And secondly does anybody have any recommendations on apps/websites I should use for stock market news and graphs so I can tell where the price is leading. Would really appreciate a response from someone I just turn 18 and I’m trying to make smart investments to multiply my money.
  • J
    Jeffrey
    Don't want pump stock. But, people panic and sell on the headlines. But, it is looking a lot more positive for Monday.
  • K
    KK
    Phase 2 clinical hold removed. Phase 3 to start. But up 70% pre market is too much. Will drop later in actual trading hour
  • a
    ali300300
    The good news the short sellers got scared from yesterday consolidation.hopefully they look for another profitable stock.
    Bullish
  • C
    Chan
    Wow...saw the press release...no wonder Stephen cohen is adding onto it...

    It is just a matter of time before FDA lifts the halt...
  • J
    J
    Retail is finally waking up to the fact that the mice died due to natural causes and preexisting condition as explained in the SEC link below.

    Cohen increased his position exponentially. The drop was a massive overreaction and the hold could be lifted anytime since as mentioned, the entire reason for the hold was due to the cancer found, which turned out not to be caused by their drug at all.

    I wouldn’t want to be shorting this, there’s a gap up to the $45+ to fill

    https://investors.protagonist-inc.com/node/9546/html
    SEC Filing | Protagonist Therapeutics, Inc.
    investors.protagonist-inc.com
  • 8
    8,891,000 views
    I put in $2,500 into $17.5 call options expiring 10/15 this baby’s growing already
Advertisement
Advertisement